Actuate Therapeutics, Inc. Earnings Per Share (Basic)
Actuate Therapeutics, Inc. (ACTU) reported Earnings Per Share (Basic) of -$0.20 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- Actuate Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.20.
- Actuate Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.24.
- Actuate Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.19.
- Actuate Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.25.
- Actuate Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$1.06.
- Actuate Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$3.26.
- Actuate Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$17.24.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.20 10-Q · filed 2026-08-14 | -$0.44 10-Q · filed 2026-08-14 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2026-03-31 | -$0.24 10-Q · filed 2026-05-14 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.68 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-12-31 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.06 10-K · filed 2026-03-26 |
| 2025-09-30 | -$0.25 10-Q · filed 2025-11-13 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.88 10-Q · filed 2025-11-13 | -$1.20 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-06-30 | -$0.30 10-Q · filed 2026-08-14 | -$0.63 10-Q · filed 2026-08-14 | -$0.96 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-03-31 | -$0.32 10-Q · filed 2026-05-14 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.97 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2024-12-31 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$3.26 10-K · filed 2026-03-26 |
| 2024-09-30 | -$0.55 10-Q · filed 2025-11-13 | -$2.03 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$4.48 10-Q · filed 2025-11-13 | -$7.40 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-06-30 | -$4.20 10-Q · filed 2025-08-14 | -$9.59 10-Q · filed 2025-08-14 | -$14.65 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$18.97 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-03-31 | -$5.40 10-Q · filed 2025-05-15 | -$10.47 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$14.80 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$18.72 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2023-12-31 | -$5.06 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$9.38 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$13.28 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$17.24 10-K · filed 2025-03-13 |
| 2023-09-30 | -$4.31 10-Q · filed 2024-11-13 | -$8.20 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$12.13 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$3.88 10-Q · filed 2024-09-24 | -$7.81 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |